Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro

J. Subhashini, S. V K Mahipal, P. Reddanna

Research output: Contribution to journalArticle

Abstract

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-inflammatory drug so far which has been approved by the FDA for adjuvant treatment of patients with familial adenomatous polyposis. The molecular mechanism responsible for the anti-cancer effects of celecoxib is not fully understood. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In view of the reported induction of apoptosis in cancer cells by cyclooxygenase-2 inhibitors, the present study is undertaken to test the effect of celecoxib on human chronic myeloid leukemia cell line, K562 and other hematopoietic cancer cell lines like Jurkat (human T lymphocytes), HL60 (human promyelocytic leukemia) and U937 (human macrophage). Treatment of these cells with celecoxib (10-100 μM) dose-dependently, reduced cell growth with arrest of the cell cycle at G0/G1 phase and induction of apoptosis. Further mechanism of apoptosis induction was elucidated in detail in K562 cell line. Apoptosis was mediated by release of cytochrome c into the cytoplasm and cleavage of poly (ADP-ribose) polymerase-1 (PARP-1). This was followed by DNA fragmentation. The level of anti-apoptotic protein Bcl-2 was decreased without any change in the pro-apoptotic Bax. Celecoxib also inhibited NF-kB activation. Celecoxib thus potentiates apoptosis as shown by MTT assay, cytochrome c leakage, PARP cleavage, DNA fragmentation, Bcl-2 downregulation and possibly by inhibiting NF-kB activation.

Original languageEnglish (US)
Pages (from-to)31-43
Number of pages13
JournalCancer Letters
Volume224
Issue number1
DOIs
StatePublished - Jun 16 2005
Externally publishedYes

Fingerprint

Celecoxib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptosis
NF-kappa B
Cyclooxygenase 2 Inhibitors
DNA Fragmentation
Cytochromes c
Cell Line
Neoplasms
Cell Cycle Resting Phase
Apoptosis Regulatory Proteins
Adenomatous Polyposis Coli
K562 Cells
G1 Phase
Myeloid Cells
Cyclooxygenase 2
Cell Cycle Checkpoints
In Vitro Techniques
Lymphoma
Cytoplasm

Keywords

  • Apoptosis
  • Bcl-2
  • Celecoxib
  • Chronic myelogenous leukemia
  • Cytochrome c
  • NF-kB
  • PARP

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. / Subhashini, J.; Mahipal, S. V K; Reddanna, P.

In: Cancer Letters, Vol. 224, No. 1, 16.06.2005, p. 31-43.

Research output: Contribution to journalArticle

Subhashini, J. ; Mahipal, S. V K ; Reddanna, P. / Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. In: Cancer Letters. 2005 ; Vol. 224, No. 1. pp. 31-43.
@article{2ae59a48ad5748528fa92d8c019c11ff,
title = "Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro",
abstract = "Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-inflammatory drug so far which has been approved by the FDA for adjuvant treatment of patients with familial adenomatous polyposis. The molecular mechanism responsible for the anti-cancer effects of celecoxib is not fully understood. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In view of the reported induction of apoptosis in cancer cells by cyclooxygenase-2 inhibitors, the present study is undertaken to test the effect of celecoxib on human chronic myeloid leukemia cell line, K562 and other hematopoietic cancer cell lines like Jurkat (human T lymphocytes), HL60 (human promyelocytic leukemia) and U937 (human macrophage). Treatment of these cells with celecoxib (10-100 μM) dose-dependently, reduced cell growth with arrest of the cell cycle at G0/G1 phase and induction of apoptosis. Further mechanism of apoptosis induction was elucidated in detail in K562 cell line. Apoptosis was mediated by release of cytochrome c into the cytoplasm and cleavage of poly (ADP-ribose) polymerase-1 (PARP-1). This was followed by DNA fragmentation. The level of anti-apoptotic protein Bcl-2 was decreased without any change in the pro-apoptotic Bax. Celecoxib also inhibited NF-kB activation. Celecoxib thus potentiates apoptosis as shown by MTT assay, cytochrome c leakage, PARP cleavage, DNA fragmentation, Bcl-2 downregulation and possibly by inhibiting NF-kB activation.",
keywords = "Apoptosis, Bcl-2, Celecoxib, Chronic myelogenous leukemia, Cytochrome c, NF-kB, PARP",
author = "J. Subhashini and Mahipal, {S. V K} and P. Reddanna",
year = "2005",
month = "6",
day = "16",
doi = "10.1016/j.canlet.2004.11.002",
language = "English (US)",
volume = "224",
pages = "31--43",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro

AU - Subhashini, J.

AU - Mahipal, S. V K

AU - Reddanna, P.

PY - 2005/6/16

Y1 - 2005/6/16

N2 - Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-inflammatory drug so far which has been approved by the FDA for adjuvant treatment of patients with familial adenomatous polyposis. The molecular mechanism responsible for the anti-cancer effects of celecoxib is not fully understood. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In view of the reported induction of apoptosis in cancer cells by cyclooxygenase-2 inhibitors, the present study is undertaken to test the effect of celecoxib on human chronic myeloid leukemia cell line, K562 and other hematopoietic cancer cell lines like Jurkat (human T lymphocytes), HL60 (human promyelocytic leukemia) and U937 (human macrophage). Treatment of these cells with celecoxib (10-100 μM) dose-dependently, reduced cell growth with arrest of the cell cycle at G0/G1 phase and induction of apoptosis. Further mechanism of apoptosis induction was elucidated in detail in K562 cell line. Apoptosis was mediated by release of cytochrome c into the cytoplasm and cleavage of poly (ADP-ribose) polymerase-1 (PARP-1). This was followed by DNA fragmentation. The level of anti-apoptotic protein Bcl-2 was decreased without any change in the pro-apoptotic Bax. Celecoxib also inhibited NF-kB activation. Celecoxib thus potentiates apoptosis as shown by MTT assay, cytochrome c leakage, PARP cleavage, DNA fragmentation, Bcl-2 downregulation and possibly by inhibiting NF-kB activation.

AB - Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-inflammatory drug so far which has been approved by the FDA for adjuvant treatment of patients with familial adenomatous polyposis. The molecular mechanism responsible for the anti-cancer effects of celecoxib is not fully understood. There is little data on the potential role of COX-2 in lymphoma pathogenesis. In view of the reported induction of apoptosis in cancer cells by cyclooxygenase-2 inhibitors, the present study is undertaken to test the effect of celecoxib on human chronic myeloid leukemia cell line, K562 and other hematopoietic cancer cell lines like Jurkat (human T lymphocytes), HL60 (human promyelocytic leukemia) and U937 (human macrophage). Treatment of these cells with celecoxib (10-100 μM) dose-dependently, reduced cell growth with arrest of the cell cycle at G0/G1 phase and induction of apoptosis. Further mechanism of apoptosis induction was elucidated in detail in K562 cell line. Apoptosis was mediated by release of cytochrome c into the cytoplasm and cleavage of poly (ADP-ribose) polymerase-1 (PARP-1). This was followed by DNA fragmentation. The level of anti-apoptotic protein Bcl-2 was decreased without any change in the pro-apoptotic Bax. Celecoxib also inhibited NF-kB activation. Celecoxib thus potentiates apoptosis as shown by MTT assay, cytochrome c leakage, PARP cleavage, DNA fragmentation, Bcl-2 downregulation and possibly by inhibiting NF-kB activation.

KW - Apoptosis

KW - Bcl-2

KW - Celecoxib

KW - Chronic myelogenous leukemia

KW - Cytochrome c

KW - NF-kB

KW - PARP

UR - http://www.scopus.com/inward/record.url?scp=19344375948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19344375948&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.11.002

DO - 10.1016/j.canlet.2004.11.002

M3 - Article

C2 - 15911099

AN - SCOPUS:19344375948

VL - 224

SP - 31

EP - 43

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -